Haematologica 2016 Jun 16
Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.
Related Questions
New answer by Medical Oncologist at Mayo Clinic College of Medicine and Science (Scottsdale) (November 26, 2019)
No. There is no role for maintenance therapy in aggressive lymphomas (transformed or not). This is based on the assumption that DLBCL is curable and randomized trials evaluati...